| scholarly article | Q13442814 |
| P356 | DOI | 10.1196/ANNALS.1351.039 |
| P698 | PubMed publication ID | 16855168 |
| P50 | author | Maurizio Cutolo | Q79075844 |
| P2093 | author name string | Alberto Sulli | |
| Bruno Seriolo | |||
| Sabrina Paolino | |||
| Daniela Fasciolo | |||
| P2860 | cites work | Cardiovascular risk factors in women with and without rheumatoid arthritis | Q28171426 |
| Coronary artery disease and rheumatoid arthritis | Q34531168 | ||
| Accelerated atherosclerosis: an extraarticular feature of rheumatoid arthritis? | Q34601733 | ||
| Clinical application of C-reactive protein for cardiovascular disease detection and prevention | Q35054464 | ||
| Influence of anti-tumour necrosis factor therapy on cardiovascular risk factors in patients with active rheumatoid arthritis | Q43049221 | ||
| Anti-tumor necrosis factor-alpha treatment improves endothelial function in patients with rheumatoid arthritis | Q44187483 | ||
| Increased thickness of the arterial intima-media detected by ultrasonography in patients with rheumatoid arthritis | Q48502988 | ||
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | rheumatoid arthritis | Q187255 |
| TNF | Q18032037 | ||
| TNF inhibitor | Q1536078 | ||
| P304 | page(s) | 414-419 | |
| P577 | publication date | 2006-06-01 | |
| P1433 | published in | Annals of the New York Academy of Sciences | Q2431664 |
| P1476 | title | Effects of anti-TNF-alpha treatment on lipid profile in patients with active rheumatoid arthritis | |
| P478 | volume | 1069 |
| Q37728928 | A systematic review of the effect of TNF-alpha antagonists on lipid profiles in patients with rheumatoid arthritis |
| Q47261263 | Anti-tumour necrosis factor-alpha therapy increases body weight in patients with chronic plaque psoriasis: a retrospective cohort study. |
| Q35910652 | ApoM Suppresses TNF-α-Induced Expression of ICAM-1 and VCAM-1 Through Inhibiting the Activity of NF-κB |
| Q36238859 | Atherogenic index and high-density lipoprotein cholesterol as cardiovascular risk determinants in rheumatoid arthritis: the impact of therapy with biologicals |
| Q36596894 | Atherogenic lipid profiles and its management in patients with rheumatoid arthritis |
| Q37064901 | Beyond the joints in rheumatoid arthritis: Effects of adalimumab on hematologic and lipid indices |
| Q38937245 | Cardiovascular Safety of Tocilizumab Versus Tumor Necrosis Factor Inhibitors in Patients With Rheumatoid Arthritis: A Multi-Database Cohort Study |
| Q36901936 | Changes in lipoproteins associated with methotrexate or combination therapy in early rheumatoid arthritis: results from the treatment of early rheumatoid arthritis trial. |
| Q34124686 | Comparison of Tripterygium wilfordii Hook F versus sulfasalazine in the treatment of rheumatoid arthritis: a randomized trial |
| Q37282484 | Comparison of lipid and lipid-associated cardiovascular risk marker changes after treatment with tocilizumab or adalimumab in patients with rheumatoid arthritis |
| Q24630541 | Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study |
| Q35029916 | Dyslipidaemia in rheumatological autoimmune diseases |
| Q37405950 | Effects of anti-TNF-α treatment on lipid profile in rheumatic diseases: an analytical cohort study. |
| Q37465404 | Effects of golimumab, an anti-tumour necrosis factor-α human monoclonal antibody, on lipids and markers of inflammation |
| Q46085890 | Effects of infliximab therapy on abdominal fat and metabolic profile in patients with Crohn's disease |
| Q60809264 | Effects of the anti-interleukin-6 receptor antibody, tocilizumab, on serum lipid levels in patients with rheumatoid arthritis |
| Q36830130 | Etanercept: a review of its use in the management of rheumatoid arthritis |
| Q37949664 | IL-6/IL-6 receptor system and its role in physiological and pathological conditions |
| Q79610823 | Impact of TNF inhibition on insulin resistance and lipids levels in patients with rheumatoid arthritis |
| Q39062398 | Inflammation: A Novel Therapeutic Target/Direction in Atherosclerosis. |
| Q35127601 | Infliximab induces increase in triglyceride levels in psoriatic arthritis patients. |
| Q34346418 | Infliximab therapy increases body fat mass in early rheumatoid arthritis independently of changes in disease activity and levels of leptin and adiponectin: a randomised study over 21 months |
| Q64102046 | Inhibitory effect of tanshinone IIA on inflammatory response in rheumatoid arthritis through regulating β-arrestin 2 |
| Q40003399 | Interleukin-6 inhibitors in the treatment of rheumatoid arthritis. |
| Q38181566 | Lipid profile changes in patients with rheumatic diseases receiving a treatment with TNF-α blockers: a meta-analysis of prospective studies |
| Q48239956 | Metabolic parameters in psoriatic patients treated with interleukin-12/23 blockade (ustekinumab). |
| Q34162072 | Modifications in lipid levels are independent of serum TNF-α in rheumatoid arthritis: results of an observational 24-week cohort study comparing patients receiving etanercept plus methotrexate or methotrexate as monotherapy |
| Q36204149 | Modulation of lipoprotein plasma concentrations during long-term anti-TNF therapy in patients with active rheumatoid arthritis |
| Q37084274 | Psoriasis comorbidities |
| Q82076745 | Rheumatoid arthritis and cardiovascular disease |
| Q35954629 | Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab |
| Q34559884 | TNF-alpha decreases ABCA1 expression and attenuates HDL cholesterol efflux in the human intestinal cell line Caco-2 |
| Q92885360 | Targeting Inflammation to Reduce Atherosclerotic Cardiovascular Risk in People With HIV Infection |
| Q35429154 | The roles of interleukin-6 in the pathogenesis of rheumatoid arthritis |
| Q80932376 | Tocilizumab for rheumatoid and juvenile idiopathic arthritis |
| Q36464352 | Traditional cardiovascular risk factors, inflammation and cardiovascular risk in rheumatoid arthritis |
| Q37625670 | Treating inflammation in atherosclerotic cardiovascular disease: emerging therapies |
| Q58329681 | Treatment with low-dose prednisolone is associated with altered body composition but no difference in bone mineral density in rheumatoid arthritis patients: a controlled cross-sectional study |
| Q37630351 | Vascular effects of biologic agents in RA and spondyloarthropathies |
| Q37588725 | Will treatment of rheumatoid arthritis with an IL-6R inhibitor help facilitate the 'age of remission'? |
Search more.